Elevance Health, Inc. $ELV Stock Bought by Sanders Capital LLC

Sanders Capital LLC boosted its position in Elevance Health, Inc. (NYSE:ELV) by 0.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 5,830,605 shares of the company’s stock after purchasing an additional 5,581 shares during the period. Elevance Health comprises about 2.2% of Sanders Capital LLC’s portfolio, making the stock its 14th biggest holding. Sanders Capital LLC’s holdings in Elevance Health were worth $2,267,056,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ELV. BlackRock Inc. purchased a new stake in Elevance Health in the second quarter worth $7,344,424,000. Bank of New York Mellon Corp bought a new stake in shares of Elevance Health in the second quarter valued at $1,246,349,000. Legal & General Group Plc purchased a new position in shares of Elevance Health during the 2nd quarter valued at $688,469,000. Amundi lifted its position in shares of Elevance Health by 145.7% during the 1st quarter. Amundi now owns 2,693,664 shares of the company’s stock valued at $788,570,000 after buying an additional 1,597,497 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Elevance Health during the 2nd quarter valued at $591,084,000. 89.24% of the stock is owned by institutional investors.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Elevance Health Stock Performance

Shares of NYSE:ELV traded down $5.83 during trading on Friday, hitting $426.17. 1,443,875 shares of the company were exchanged, compared to its average volume of 1,442,885. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $450.69. The stock has a 50 day moving average of $412.92 and a 200 day moving average of $373.58. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. The company has a market cap of $92.08 billion, a PE ratio of 18.17, a P/E/G ratio of 1.97 and a beta of 0.63.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. During the same period in the previous year, the business earned $6.03 earnings per share. The firm’s quarterly revenue was up .7% compared to the same quarter last year. As a group, equities research analysts predict that Elevance Health, Inc. will post 29.16 EPS for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is currently 29.34%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ELV shares. Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley upped their price objective on shares of Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a report on Thursday, October 22nd. Mizuho set a $490.00 target price on shares of Elevance Health in a research report on Friday, October 23rd. UBS Group lifted their target price on shares of Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Finally, Royal Bank Of Canada boosted their price target on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research report on Thursday, October 22nd. Fifteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and an average target price of $456.48.

Insider Activity

In other news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $440.00, for a total value of $572,000.00. Following the sale, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Kaye sold 10,584 shares of the stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the sale, the chief financial officer directly owned 19,919 shares in the company, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.34% of the stock is owned by company insiders.

Elevance Health Company Profile

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.